Risk Intelligence
Working capital days elevated due to inventory buildup
View Risks →Aether Industries delivered a strong Q3 FY26 with consolidated revenue of ₹317.1 crore (+44% YoY) and EBITDA of ₹108.3 crore (+75% YoY), driven by robust volume growth in large-scale manufacturing (25% YoY) and ramp-up in contract manufacturing.
Financial stats pending filing verification
Aether Industries delivered a strong Q3 FY26 with consolidated revenue of ₹317.1 crore (+44% YoY) and EBITDA of ₹108.3 crore (+75% YoY), driven by robust volume growth in large-scale manufacturing (25% YoY) and ramp-up in contract manufacturing. EBITDA margin expanded 600 bps YoY to 34%, aided by operating leverage and a one-time insurance claim. Management highlighted completion of Site 3+ and first two blocks of Site 5, with commercial production imminent. The company added five new clients and three new LSM products. Guidance includes 70% revenue from CRAMS/CM over time, with near-term capacity utilization targets of 45-50% for new sites. Key risk: working capital days increased to 160 due to inventory buildup for new sites, though management expects improvement as CM share rises.
एथर इंडस्ट्रीज ने तीसरी तिमाही में शानदार प्रदर्शन किया। कंपनी की कुल कमाई ₹317.1 करोड़ रही, जो पिछले साल से 44% ज्यादा है। मुनाफा (EBITDA) ₹108.3 करोड़ रहा, जो 75% बढ़ा। इसकी वजह बड़े पैमाने पर उत्पादन में 25% बढ़ोतरी और ठेके पर निर्माण (कॉन्ट्रैक्ट मैन्युफैक्चरिंग) का बढ़ना है। कंपनी का मुनाफा मार्जिन 34% हो गया, जो पिछले साल से 6% ज्यादा है। इससे कंपनी को बीमा क्लेम और बेहतर परिचालन से फायदा मिला। प्रबंधन ने बताया कि साइट 3+ और साइट 5 के दो ब्लॉक तैयार हैं, जल्द उत्पादन शुरू होगा। कंपनी ने पांच नए ग्राहक और तीन नए उत्पाद जोड़े। भविष्य में 70% कमाई ठेके पर निर्माण से होगी। नई साइटों की क्षमता 45-50% तक इस्तेमाल होने की उम्मीद है। जोखिम: कार्यशील पूंजी के दिन 160 हो गए, लेकिन ठेके पर निर्माण बढ़ने से इसमें सुधार होगा।
Working capital days elevated due to inventory buildup
View Risks →Full transcript text is available on this route.
Read Transcript →Volume growth in LSM vertical was over 25% year-on-year, indicating strong demand.
Sales from Site 4 increased 20% quarter-on-quarter to ₹60 crore, driven by Baker Hughes contract.
43% of sales came from contract exclusive manufacturing, with CRAMS at 8% and LSM at 41%.
Export revenue stood at 36% of total revenue, with domestic at 64%.
Commercial production from Site 3+ and first two blocks of Site 5 will commence shortly, with water/solvent trials already started.
Net working capital cycle increased to 160 days from 149 days as of September 2025, mainly due to inventory buildup for new sites.
View Risks →